Brauckhoff M, Gimm O, Brauckhoff K, Ukkat J, Thomusch O, Dralle H
Department of General, Visceral and Vascular Surgery, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Strasse 40, 06097 Halle/Saale, Germany.
Langenbecks Arch Surg. 2001 Nov;386(6):434-9. doi: 10.1007/s004230100252. Epub 2001 Oct 5.
Calcitonin is a sensitive marker for medullary thyroid carcinoma. Normalisation of calcitonin levels following resection of medullary thyroid carcinoma has been described after a few hours; however, it may be observed more than 4 weeks after surgery. The aim of this study was to correlate the postoperative calcitonin kinetics with preoperative calcitonin levels and tumour stage. Furthermore, we wanted to test the prognostic impact of the calcitonin kinetics. Therefore, only patients with postoperative normalisation of calcitonin levels (biochemical cure) were included in this study.
Fourteen biochemically cured patients were analysed, including measurement of postoperative basal and pentagastrin-stimulated calcitonin concentration. With respect to the time of postoperative basal calcitonin normalisation, patients were classified into two groups: (A) patients with normalisation of basal calcitonin levels within 24 h and (B) patients with normalisation of basal calcitonin levels later than 24 h postoperatively.
Eight patients were found to have normalisation of basal calcitonin levels within 24 h (group A). In the remaining six patients (group B), the period to normalisation of basal calcitonin levels varied from 6 days to 14 days and longer. There were no differences between the two groups with regard to tumour size, number and pattern of lymph node metastases and tumour stage. However, preoperative basal calcitonin levels were significantly different (258 ng/ml vs 955 ng/ml, P<0.01). In the group with slow-decreasing calcitonin levels, no strong correlation between the preoperative level and the postoperative time to normalisation of basal calcitonin levels could be established, which may be due to the small number of patients. After a median follow-up of 21 months, no patient developed tumour recurrence. However, an increased basal calcitonin level was observed in one patient from group B. All other patients had normal basal and peak calcitonin levels.
Using a highly sensitive calcitonin assay, we demonstrated that normalisation of basal calcitonin levels may be delayed in patients suffering from medullary thyroid carcinoma. The lack of correlation of preoperative levels and the time to normalisation of the basal calcitonin levels, as well as the positive pentagastrin test in some of the patients, argues that this phenomenon is not simply due to prolonged biochemical calcitonin elimination. Nevertheless, a prognostic influence could not be shown in this study due to the short follow up-period. Further investigations and a longer follow-up are necessary to determine the nature and the prognostic impact of delayed normalisation of calcitonin levels.
降钙素是甲状腺髓样癌的一个敏感标志物。甲状腺髓样癌切除术后数小时内降钙素水平可恢复正常;然而,也可能在术后4周以上才出现。本研究的目的是将术后降钙素动力学与术前降钙素水平及肿瘤分期相关联。此外,我们想测试降钙素动力学的预后影响。因此,本研究仅纳入降钙素水平术后恢复正常(生化治愈)的患者。
分析了14例生化治愈的患者,包括测定术后基础及五肽胃泌素刺激后的降钙素浓度。根据术后基础降钙素恢复正常的时间,将患者分为两组:(A)组为基础降钙素水平在24小时内恢复正常的患者,(B)组为基础降钙素水平在术后24小时后恢复正常的患者。
8例患者基础降钙素水平在24小时内恢复正常(A组)。其余6例患者(B组)基础降钙素水平恢复正常的时间从6天到14天及更长。两组在肿瘤大小、淋巴结转移的数量和模式以及肿瘤分期方面无差异。然而,术前基础降钙素水平有显著差异(258 ng/ml对955 ng/ml,P<0.01)。在降钙素水平下降缓慢的组中,术前水平与基础降钙素水平恢复正常的术后时间之间未建立强烈相关性,这可能是由于患者数量较少。中位随访21个月后,无患者出现肿瘤复发。然而,B组有1例患者基础降钙素水平升高。所有其他患者基础及峰值降钙素水平均正常。
使用高灵敏度的降钙素检测方法,我们证明甲状腺髓样癌患者基础降钙素水平的恢复可能会延迟。术前水平与基础降钙素水平恢复正常的时间缺乏相关性,以及部分患者五肽胃泌素试验呈阳性,表明这种现象并非仅仅是由于降钙素生化清除时间延长所致。然而,由于随访期短,本研究未能显示出预后影响。需要进一步研究和更长时间的随访来确定降钙素水平恢复延迟的性质及其预后影响。